Early trial tests 'Ready-Made' cell therapy for tough blood cancers
NCT ID NCT07316907
Summary
This is an early safety study testing a new type of cell therapy for adults with B-cell blood cancers that have returned or not responded to standard treatments. The therapy, called 19UCART, uses genetically modified immune cells from a donor (not the patient) to target and kill cancer cells. The main goals are to see if this 'off-the-shelf' approach is safe and to look for early signs that it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.